Some studies suggest combining this with another serum agent—HE4 (cut-off = 70 pmol/L [18]) and preoperative inflammatory markers for differential diagnosis of ovarian cancer from benign lesions [19]. This evidence concerns the gene WFDC2 and ovarian cancer.